Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin

Journal of Neurology

Volumn 250, Issue 2, 2003, Pages 188-193

  Kramer H H ^a   Angerer, C ^b   Erbguth, F ^b   Schmelz, M ^b   Birklein, Frank ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Botulinum Toxin A; Hyperalgesia; Iodine starch staining; Laser Doppler imaging; Neurogenic inflammation; Sweating

Indexed keywords

BOTULINUM TOXIN A; SODIUM CHLORIDE;

ADULT; ALLODYNIA; ANALGESIA; ANHIDROSIS; ARTICLE; BLOOD FLOW; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEADACHE; HUMAN; HYPERALGESIA; MALE; PAIN; PRICK TEST; PRIORITY JOURNAL; PROTEIN SECRETION; REFLEX; STAINING; SWEATING; TRANSCUTANEOUS NERVE STIMULATION;

ADULT; AXONS; BOTULINUM TOXIN TYPE A; ELECTRIC STIMULATION; FEMALE; HUMANS; HYPERALGESIA; HYPOHIDROSIS; MALE; NERVE FIBERS; NEUROGENIC INFLAMMATION; NOCICEPTORS; PAIN; PAIN MEASUREMENT; PSYCHOPHYSICS; SKIN;

EID: 0037322405     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-003-0971-x     Document Type: Article

References (47)

1. Bickel A, Krämer HH, Hilz MJ, Birklein F, Neundorfer B, Schmelz M (2002) Assessment of the neurogenic flare reaction in small fiber neuropathies. Neurology 59:917-919
2. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM (2000) Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 123:669-676
3. Birklein F, Erbguth F (2000) Sudomotor testing discriminates between subjects with and without antibodies against botulinum toxin A - a preliminary observation. Mov Disord 15:146-149
4. Birklein F, Walther D, Bigalke H, Winterholler M, Erbguth F (2002) Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies. Ann Neurol 52:68-73
5. Blochl A (1998) SNAP-25 and syntaxin, but not synaptobrevin 2, cooperate in the regulated release of nerve growth factor. Neuroreport 9:1701-1705
6. Braune C, Erbguth F, Birklein F (2001) Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injections: measured by sudometry. Br J Dermatol 144:111-117
7. Brin MF (1997) Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 6:S146-S168
8. Bushara KO, Park DM, Jones JC, Schutta HS (1996) Botulinum toxin - a possible new treatment for axillary hyperhidrosis. Clin Exp Dermatol 21:276-278
9. Cheshire WP, Abashian SW, Mann JD (1994) Botulinum toxin in the treatment of myofascial pain syndrome (see comments). Pain 59:65-69
10. Drobik C, Laskawi R (1995) Frey's syndrome: treatment with botulinum toxin. Acta Otolaryngol Stockh 115:459-461
11. Gobel H, Heinze A, Heinze-Kuhn K, Austermann K (2001) Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 91:195-199
12. Grazko MA, Polo KB, Jabbari B (1995) Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 45:712-717
13. Halpern JL, Neale EA (1995) Neurospecific binding, internalization, and retrograde axonal transport. Curr Top Microbiol Immunol 195:221-241
14. Hobson DE, Gladish DF (1997) Botulinum toxin injection for cervicogenic headache. Headache 37:253-255
15. Holzer P (1998) Neurogenic vasodilatation and plasma leakage in the skin. Gen Pharmacol 30:5-11
16. Hua XY, Chen P, Marsala M, Yaksh TL (1999) Intrathecal substance P-induced thermal hyperalgesia and spinal release of prostaglandin E2 and amino acids. Neuroscience 89:525-534
17. Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, Shimizu K (2000) Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 44:106-109
18. Jankovic J, Schwartz KS (1993) Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 43:834-836
19. Jeftinija SD, Jeftinija KV, Stefanovic G (1997) Cultured astrocytes express proteins involved in vesicular glutamate release. Brain Res 750:41-47
20. Koltzenburg M, Torebjork HE, Wahren LK (1994) Nociceptor modulated central sensitization causes mechanical hyperalgesia in acute chemogenic and chronic neuropathic pain. Brain 117:579-591
21. Koppert W, Dern SK, Sittl R, Albrecht S, Schuttler J, Schmelz M (2001) A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. Anesthesiology 95:395-402
22. LaMotte RH, Shain CN, Simone DA, Tsai EFP (1991) Neurogenic hyperalgesia psychophysical studies of underlying mechanisms. J Neurophysiol 66:190-211
23. Low PA, Kennedy WR (1997) Cutaneous effectors as indicators of abnormal sympathetic function. In: Morris JL, Gibbins IJ (eds) Autonomic innervation of the skin. Harwood academic publishers, Amsterdam, pp 165-212
24. McMahon HT, Foran P, Dolly JO, Verhage M, Wiegant VM, Nicholls DG (1992) Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J Biol Chem 267:21338-21343
25. Meyer RA, Campbell JN, Raja SN (1988) Antidromic nerve stimulation in monkey does not sensitize unmyelinated nociceptors to heat. Brain Res 441:168-172
26. Minor V (1927) Ein Neues Verfahren zu der klinischen Untersuchung der Schweissabsonderung. Z Neurologie 101:302-308
27. Nichols ML, Allen BJ, Rogers SD, Ghilardi JR, Honore P, Luger NM, Finke MP, Li J, Lappi DA, Simone DA, Mantyh PW (1999) Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science 286:1558-1561
28. Pamphlett R (1989) Early terminal and nodal sprouting of motor axons after botulinum toxin. J Neurol Sci 92:181-192
29. Porta M (2000) A comparative trial of botulinum toxin type A and methyl-prednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 85:101-105
30. Porta M (2000) A Comparative Trial of Botulinum Toxin Type A and Methyl-prednisolone for the Treatment of Tension-Type Headache. Curr Rev Pain 4:31-35
31. Purkiss J, Welch M, Doward S, Foster K (2000) Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 59:1403-1406
32. Purkiss JR, Welch MJ, Doward S, Foster KA (1997) Capsaicin stimulates release of substance P from dorsal root ganglion neurons via two distinct mechanisms. Biochem Soc Trans 25:542S
33. Riedl B, Nischik M, Birklein F, Neundörfer B, Handwerker HO (1998) Spatial extension of sudomotor axon reflex sweating in human skin. J Aut Nerv Syst 69:83-88
34. Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler R (2000) Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache 40:300-305
35. Rosales RL, Arimura K, Takenaga S, Osame M (1996) Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19:488-496
36. Sauerstein K, Klede M, Hilliges M, Schmelz M (2000) Electrically evoked neuropeptide release and neurogenic inflammation differ between rat and human skin. J Physiol (London) 529:803-810
37. Schmelz M, Luz O, Averbeck B, Bickel A (1997) Plasma extravasation and neuropeptide release in human skin as measured by intradermal microdialysis. Neurosci Lett 230:117-120
38. Schmelz M, Michael K, Weidner C, Schmidt R, Torebjörk HE, Handwerker HO (2000) Which nerve fibers mediate the axon reflex flare in human skin? Neuroreport 11:645-648
39. Schmelz M, Schmidt R, Ringkamp M, Forster C, Handwerker HO, Torebjork HE (1996) Limitation of sensitization to injured parts of receptive fields in human skin C-nociceptors. Exp Brain Res 109:141-147
40. Silberstein S, Mathew N, Saper J, Jenkins S (2000) Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40:445-450
41. Tsuda M, Ueno S, Inoue K (1999) In vivo pathway of thermal hyperalgesia by intrathecal administration of alpha,beta-methylene ATP in mouse spinal cord: involvement of the glutamate-NMDA receptor system. Br J Pharmacol 127:449-456
42. Weidner C, Klede M, Rukwied R, Lischetzki G, Neisius U, Skov PS, Petersen LJ, Schmelz M (2000) Acute Effects of Substance P and Calcitonin Gene-Related Peptide in Human Skin - A Microdialysis Study. J Invest Dermatol 115:1015-1020
43. Weidner C, Schmelz M, Schmidt R, Hansson B, Handwerker HO, Torebjork HE (1999) Functional attributes discriminating mechano-insensitive and mechano-responsive C nociceptors in human skin. J Neurosci 19:10184-10190
44. Welch MJ, Purkiss JR, Foster KA (2000) Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38:245-258
45. Wilkins RW, Newman HW, Doupe J (1938) The local sweat response to faradic stimulation. Brain 61:290-297
46. Yokosawa N, Suga K, Kimura K, Tsuzuki K, Fujii N, Oguma K, Yokosawa H (1994) Exogenous zinc ion is required for inhibitory activity of botulinum neurotoxin C1 against norepinephrine release and its endopeptidase activity toward substance P. Biochem Mol Biol Int 32:455-463
47. Zwart JA, Bovim G, Sand T, Sjaastad O (1994) Tension headache: botulinum toxin paralysis of temporal muscles. Headache 34:458-462